WEBBasel, August 22, 2020 — Novartis announced today that the Phase III COMBI-i study evaluating the investigational immunotherapy spartalizumab (PDR001), in combination with the targeted therapies Tafinlar ® (dabrafenib) and Mekinist ® (trametinib), did not meet its primary endpoint of investigator-assessed progression-free survival.
DA:79PA:99MOZ Rank:11
Novartis reports late-breaking data from Phase III COMBI-i trial of
WEBBasel, September 19, 2020 — Novartis announced today detailed results from the Phase III COMBI-i trial evaluating the investigational immunotherapy spartalizumab (PDR001) in combination with the targeted therapies Tafinlar ® (dabrafenib) and Mekinist ® (trametinib) compared to Tafinlar + Mekinist alone 1.
DA:10PA:10MOZ Rank:12
Phase II, Randomized Study of Spartalizumab (PDR001), an Anti ... - PubMed
WEBDec 1, 2021 · Phase II, Randomized Study of Spartalizumab (PDR001), an Anti-PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer. Clin Cancer Res. 2021 Dec 1;27 (23):6413-6423. doi: 10.1158/1078-0432.CCR-21-0822. Epub 2021 Aug 25.
DA:5PA:41MOZ Rank:98
Phase II, Randomized Study of Spartalizumab (PDR001), an …
WEBDec 1, 2021 · Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer | Clinical Cancer Research | American Association for Cancer Research. Clinical Trials: Immunotherapy | December 01 2021.
DA:69PA:71MOZ Rank:15
A first-in-human phase 1 dose escalation study of spartalizumab (PDR001
WEBMar 15, 2020 · The anti–PD-1 antibody spartalizumab (PDR001) in combination with dabrafenib and trametinib in previously untreated patients with advanced BRAF V600-mutant melanoma: first efficacy, safety, and biomarker findings from the part 2 biomarker cohort of COMBI-i.
DA:40PA:12MOZ Rank:67
A first-in-human phase 1 dose escalation study of spartalizumab (PDR001
WEBAbstract. Background: Spartalizumab is a humanized IgG4κ monoclonal antibody that binds programmed death-1 (PD-1) and blocks its interaction with PD-L1 and PD-L2. This phase 1/2 study was designed to assess the safety, pharmacokinetics, and preliminary efficacy of spartalizumab in patients with advanced or metastatic solid tumors.
DA:3PA:47MOZ Rank:30
Activity & safety of spartalizumab (PDR001) in patients (pts) with
WEBBackground: PDR001 is a high-affinity, humanized, anti-PD-1 IgG4 antibody that blocks PD-L1 & PD-L2 binding to PD-1. A phase 2, multi-center study assessed the efficacy & safety of PDR001 in pts with nonfunctional well- & poorly-differentiated (diff) …
DA:29PA:41MOZ Rank:42
Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in
WEBJun 1, 2018 · Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with anaplastic thyroid cancer. Authors : Lori J. Wirth , Ekkehard Eigendorff , Jaume Capdevila , Luis G. Paz-Ares , Chia-Chi Lin , Matthew H. Taylor , Rodryg Ramlau , …
DA:96PA:1MOZ Rank:83
Phase I study of the antiprogrammed cell death‐1 Ab …
WEBSpartalizumab (PDR001) is a humanized IgG4/κ mAb directed against human PD‐1; it binds to PD‐1 with high affinity, and blocks the binding of PD‐L1 and PD‐L2 to PD‐1. 9 Clinical data from a parallel global phase I/II dose‐escalation and ‐expansion study (NCT02404441) of spartalizumab in patients with advanced malignancies showed a ...
DA:21PA:96MOZ Rank:85
Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in
WEBPhase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer. Background: Spartalizumab is a humanized IgG4 anti-PD1 mAb, which has previously shown favorable PK and safety, and preliminary clinical activity.
